From advanced biologics and cell therapies to increasingly stringent regulatory expectations, today’s pharmaceutical manufacturing environments dem...
As clinical development grows more complex and globally interconnected, biotech companies are under increasing pressure to build CRO partnerships that deli...
As biologics, advanced therapies, and specialised injectable medicines continue to reshape the pharmaceutical landscape, the demand for agile and h...
As healthcare shifts toward precision medicine and data-driven care, continuous biochemical monitoring is emerging as a transfo...
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income ...
Central nervous system (CNS) cancers remain among the most difficult diseases to treat in oncology, with limited therapeutic options, complex deliv...
Fluid overload remains one of the most complex and costly challenges in cardiorenal care, particularly for patients who no longer respond to conventional d...
As pharmaceutical companies continue to face high attrition rates, rising development costs and increasingly complex clinical datasets, the industry is sea...
As biologics manufacturing operations become increasingly complex, biopharma companies are under growing pressure to improve efficiency, strengthen...
Regenerative medicine is entering a pivotal phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative The...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended Ma...
"In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand f...
The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...
In this exclusive BioPharma Boardroom interaction, Thierry Van Nieuwenhove, CEO of Quotient Sciences, explores why nearly 90% of drug candidates fail and w...
© 2026 Biopharma Boardroom. All Rights Reserved.
